KONINKLIJKE PHILIPS NV

KONINKLIJKE PHILIPS NV is a US-listed company materially exposed to Sleep & Breathing Health Platforms.

Koninklijke Philips N.V. is a Netherlands-based health-technology company. It exited the consumer-electronics and domestic-appliances businesses over the past decade and now operates three reportable segments:

1. Diagnosis & Treatment — medical imaging, image-guided therapy, and related informatics.
2. Connected Care — patient monitoring, sleep and respiratory care, and hospital information/telehealth.
3. Personal Health — oral care, personal care, and mother-and-child care.

This segmentation is drawn from Philips’ public business description. Source: S20F24; SPHILIPS.

The exact segment percentages and euro amounts are load-bearing for conviction scoring. I cannot verify them against the actual SEC filing in this pass, so they are marked as unverified.

If the memorized segment mix is approximately correct, Philips is now primarily a capital-equipment and hospital-technology business, with a smaller but more consumer-facing Personal Health durable-goods franchise.

Philips monetizes through multiple mechanisms:

• Capital equipment sales: MRI, CT, ultrasound, interventional X-ray, patient monitors, ventilators, and similar systems sold to hospitals and integrated delivery networks.
• Service contracts: multi-year maintenance, spare parts, software upgrades, and technical support.
• Software and informatics: hospital image management, analytics, and AI-enabled workflow tools sold as licenses or subscriptions.
• Consumables: proprietary disposables in monitoring, respiratory care, and image-guided therapy.
• Direct-to-consumer product sales: Sonicare toothbrush heads, Avent mother-and-child products, shavers, and personal-care devices sold through retailers and e-commerce.

Source: SPHILIPS; SPROD.

The following figures are central to the thesis and must be checked against the Form 20-F income statement:

• Group sales: approximately €18.0 billion for FY2024 — needs primary source validation.
• IFRS income from operations: approximately €514 million for FY2024 — needs primary source validation.
• IFRS operating margin: approximately 2.9% if both figures are correct — needs primary source validation.
• Adjusted EBITA margin: approximately 11.5% for FY2024 — needs primary source validation.
• Gross margin: not separately verified — needs primary source validation.

The gap between the IFRS operating margin and the adjusted EBITA margin is material and is expected to reflect one-time charges, restructuring, quality/legal remediation, or amortization. That gap should be sourced directly from the 20-F reconciliation. Source: S20F24; not cross-verified; [SINGLE-SOURCE] for issuer-reported margin.

• Hospitals and health systems pay for imaging, monitoring, and therapy equipment through capital budgets and operating budgets.
• Outpatient imaging centers, cardiology labs, and ambulatory surgery centers pay for D&T equipment.
• Group purchasing organizations and integrated delivery networks negotiate multi-site contracts.
• Consumers pay for Personal Health products through retail and online channels.
• Distributors and government tenders are used in international markets.

Philips’ filings generally describe sales through direct channels and distributors; no single end-customer is typically disclosed as accounting for more than 10% of revenue. This specific statement should be verified against the Form 20-F customer-concentration note. Source: S20F24; needs primary source validation.

I do not have a verified list of named top customers from the 20-F. Philips generally does not name hospital customers in its annual report; it discusses customer classes and channels. Therefore, no specific customer name is included here because none is verified from a filing. Source: S20F24; no named top-customer data verified.

1. Hospital imaging and radiology departments

• Buyers: radiology directors, imaging administrators, hospital CIOs, physics teams, procurement.
• Products: MRI, CT, ultrasound, X-ray, PACS, enterprise imaging.
• Decision drivers: image quality, uptime, dose management, AI workflow, total cost of ownership.

2. Interventional cardiology, surgery, and image-guided therapy centers

• Buyers: cath-lab directors, interventional cardiologists, vascular surgeons, operating-room administrators.
• Products: image-guided therapy systems, interventional X-ray, related consumables.
• Decision drivers: procedure workflow, clinical outcomes, installed clinical knowledge, service responsiveness.

3. ICU, emergency, and hospital biomedical teams

• Buyers: critical-care nursing leadership, biomedical engineering, hospital IT, chief medical officers.
• Products: patient monitors, ventilators, telehealth platforms, AEDs, data infrastructure.
• Decision drivers: interoperability, alarm management, reliability, existing hospital network, regulatory compliance.

4. Consumers and retail customers

• Buyers: individual consumers, mass merchants, e-commerce marketplaces.
• Products: Sonicare, shavers, Avent, personal-care devices.
• Decision drivers: brand trust, dental/professional recommendation, replacement cycles, price.

5. Distributors and government tenders

• Buyers: international distributors, public-health authorities, defense/emergency procurement.
• Products: broad portfolio, often standardized configurations.
• Decision drivers: tendering compliance, total cost, local service capability.

No specific named customers are included because none are verified from the filings. Source: S20F24; SPROD; qualitative only.

• PHG — Koninklijke Philips N.V. — its Respironics CPAP/BiPAP devices were subject to the FDA Class I PE-PUR foam recall. [FDA recall notice](https://www.fd

• - PHG — Koninklijke Philips N.V. — its Respironics CPAP/BiPAP devices were subject to the FDA Class I PE-PUR foam recall. [FDA recall notice](https://www.fd source

Using the model input:

\[

\text{Adjusted EBITA} = 18,023 \times 0.115 = €2,073m

\]

\[

\text{FCF conversion} = \frac{906}{2,073} = 0.437

\]

\[

\text{FCF conversion} \approx 43.7\%

\]

Interpretation: Under these unverified inputs, Philips converted roughly 44% of adjusted EBITA into free cash flow. That is not necessarily poor for a capital-equipment and post-recall remediation business, but it is worth comparing with peers such as GE HealthCare or ResMed.

If sales grow 3%:

\[

\Delta \text{Sales} = 18,023 \times 0.03 = €541m

\]

Assume incremental adjusted EBITA margin of 30%:

\[

\Delta \text{Adjusted EBITA} = 541 \times 0.30 = €162m

\]

New adjusted EBITA:

\[

2,073 + 162 = €2,235m

\]

New adjusted EBITA margin:

\[

\frac{2,235}{18,023 + 541} = \frac{2,235}{18,564} \approx 12.0\%

\]

Sensitivity of incremental margin: